[{"id":"6cdcc31a-0ce3-49ee-bdf9-1051ddeebebe","acronym":"TROPION-Lung10","url":"https://clinicaltrials.gov/study/NCT06357533","created_at":"2024-04-10T18:42:49.173Z","updated_at":"2025-02-25T16:55:47.733Z","phase":"Phase 3","brief_title":"Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations","source_id_and_acronym":"NCT06357533 - TROPION-Lung10","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1 • TACSTD2","pipe":" | ","alterations":" TROP2 positive","tags":["PD-L1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TROP2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 675","initiation":"Initiation: 04/11/2024","start_date":" 04/11/2024","primary_txt":" Primary completion: 04/24/2028","primary_completion_date":" 04/24/2028","study_txt":" Completion: 05/24/2030","study_completion_date":" 05/24/2030","last_update_posted":"2025-02-04"},{"id":"34784849-bd53-4fa3-93bd-7d5283db1211","acronym":"NIR","url":"https://clinicaltrials.gov/study/NCT05708144","created_at":"2024-01-27T07:17:55.352Z","updated_at":"2024-07-02T16:35:24.800Z","phase":"","brief_title":"NIR Fluorescent Molecular Probe for the Identification of Breast Tissue","source_id_and_acronym":"NCT05708144 - NIR","lead_sponsor":"Xiang'an Hospital of Xiamen University","biomarkers":" TACSTD2","pipe":" | ","alterations":" TROP2 positive","tags":["TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TROP2 positive"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 02/17/2023","start_date":" 02/17/2023","primary_txt":" Primary completion: 10/30/2023","primary_completion_date":" 10/30/2023","study_txt":" Completion: 10/30/2023","study_completion_date":" 10/30/2023","last_update_posted":"2024-01-01"},{"id":"95e30619-7cb6-49e5-a70d-9b038aaf7b08","acronym":"","url":"https://clinicaltrials.gov/study/NCT02425800","created_at":"2021-01-18T11:36:14.829Z","updated_at":"2024-07-02T16:36:25.031Z","phase":"","brief_title":"Human Prostate Tissue Model to Maintain and Study Prostate Cancer Stem Cells","source_id_and_acronym":"NCT02425800","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" CTNNB1 • CDH1","pipe":" | ","alterations":" TROP2 positive","tags":["CTNNB1 • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TROP2 positive"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 07/28/2015","start_date":" 07/28/2015","primary_txt":" Primary completion: 11/05/2018","primary_completion_date":" 11/05/2018","study_txt":" Completion: 08/03/2021","study_completion_date":" 08/03/2021","last_update_posted":"2021-09-01"}]